Skip to content

The efficacy of blood transfusions to improve microcirculatory density in anemic patients.

The efficacy of blood transfusions to improve microcirculatory density in anemic patients. - The efficacy of blood transfusions in anemic patients.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35135
Enrollment
160
Registered
2010-05-20
Start date
2010-08-10
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intensive care patienten die met bloedtransfusie behandeld worden anemia non-sepsis sepsis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Intensive care patients receiving blood transfusion therapy 2.Approval from the physician that will be treating the patients 3.Informed consent from each participating patient 4.Patients older than 18 years old 5.Transfusion of blood from storage age less than 1 week and more than 3 weeks 6.Patients in whom the doses of vasopressor/inotropic and sedative/analgesic agents are kept constant

Exclusion criteria

Exclusion criteria: 1. Patients that did not sign an informed consent 2. Patients younger than 18 years 3. Indication for irradiated and/or washed blood products

Design outcomes

Primary

MeasureTime frame
Noninvasive measurements: Sidestream Dark-Field (SDF) Imaging-microcirculation quantification: FCD (functional capillary density), MFI (microvascular flow index) Fibre spectrophotometry and laser Doppler flowmetry (O2C): Microcirculatory hemoglobin saturation and flow in superficial layers Near-infrared spectroscopy (NIRS): Microcirculatory hemoglobin saturation and flow in deep layers Invasive measurements: Blood sample

Secondary

MeasureTime frame
N.v.t.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)